Coast Bancorp (TBP) – PRNewswire
-
Tetra Bio-Pharma Announces Listing to OTCPink Market
-
REDUVO™ Marketing Approval on the Right Path
-
Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir
-
Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003
-
Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission
-
Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean
-
Tetra and Prepaire Jointly Apply to BARDA for Funding
-
Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean
-
Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients
-
Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean
-
Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections
-
Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug
-
Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update
-
Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting
-
Tetra Bio-Pharma Appoints Chief Financial Officer
-
Tetra Bio-Pharma Receives EMA Orphan Drug Designation for a Novel Topical Therapeutic Containing CBD
-
Tetra Bio-Pharma Announces Closing of First Tranche with Cannvalate
-
Tetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD Technology
-
Tetra Bio-Pharma and Cannvalate Enter Into Partnership
-
Tetra Bio-Pharma's QIXLEEF™ on Track After Type C Meeting with U.S. FDA
-
Tetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBD
-
Tetra Bio-Pharma Signs License Agreement with Thorne for a Prebiotic Dietary Supplement
-
Tetra Bio-Pharma Receives $4.5M from the Ministère de l'Économie et de l'Innovation/Investissement Québec
-
Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna
-
QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols
-
Tetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™
-
Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering
-
Tetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency
-
Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™
-
REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.
-
Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™
-
Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue
-
Tetra Bio-Pharma Engages Christine Caron as Patient Partner
-
Tetra Bio-Pharma Accelerates REBORN1© Trial
-
Significant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma's Innovative Drug ARDS-003
Back to TBP Stock Lookup